OKYO Pharma Limited

OKYO Pharma Limited is ready to move its dry eye disease candidate, OK-101, into Phase III and asserted that the efficacy and safety profile it has seen so far might position OK-101 to take a market-

Third Harmonic Bio Inc. could be the first biopharmaceutical company to launch an initial public offering in the US since the end of July and deliver the first biopharma IPO to raise more than $100m

The US stock market has been brutal for biopharmaceutical companies during the past year, with plummeting valuations driving companies to reprioritize their research and development plans, lay off emp

Going public has been a lucrative means of raising cash for hundreds of biopharmaceutical companies during the past few years, but with biotech stock valuations plummeting it has become increasingly d